Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.85 - Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
00:00 - 00:00 | Presenter: Sukhmani K. Padda
- Abstract
Loading...
-
+
P84 - Targeted Therapy - Clinically Focused - ALK
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P84.08 - First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis
00:00 - 00:00 | Presenter: Huamao M Lin
- Abstract
Loading...
-
+
OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease
-
+
OA06.06 - Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
17:15 - 17:25 | Presenter: David Paul Carbone
- Abstract
Loading...
-
+
PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
07:30 - 07:40 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)
- 18:00 - 20:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS02.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
18:30 - 18:40 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
IS14 - Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective
- 13:00 - 14:00
- 1/31/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS14.03 - Panel Discussion: The MDT Approach to Managing EGFR-Mutated NSCLC
13:15 - 13:45 | Presenter: Edward S. Kim, Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen L Reckamp
- Abstract
No abstract available for this presentation